Most patients with mild symptoms of COVID-19 lose their sense of taste and smell but tend to recover it quickly, according to findings from a new study.
A small but rigorous clinical trial in Argentina has found that blood plasma from recovered Covid-19 patients can keep older adults from getting seriously sick with the coronavirus — if they get the therapy within days of the onset of the illness.
As the U.S. grapples with record hospitalizations and deaths from the Covid-19 pandemic, a crucial vaccination rollout campaign is being impeded by inconsistent messaging and myriad state strategies as a new variant of the virus drives up infection rates, according to public health experts.
As Americans were transfixed by the spectacle of the Capitol under siege, the coronavirus continued to sweep across the United States.
Officials reported at least 3,963 new coronavirus deaths in the United States on Wednesday, a new single-day record, though delayed recording because of the holidays might have played a role. The daily death toll in New Hampshire, Oklahoma and Pennsylvania also set records.
Some states also reported single-day case records, while Illinois became one of five states that have now recorded their millionth case since the pandemic began.
New York’s governor threatened to fine hospitals if they don’t use their allotment of COVID-19 vaccine fast enough. His South Carolina counterpart warned health care workers they have until Jan. 15 to get a shot or move to the back of the line. California’s governor wants to use dentists to vaccinate people.
WASHINGTON — Federal officials and drugmakers, faced with a slower-than-expected rollout of the coronavirus vaccine, are racing to find ways to expand the supply, looking at lowering the required dosage and extracting more doses from the supplies they have.
Just weeks into the vaccine program, scientists at the National Institutes of Health and the drugmaker Moderna are analyzing data to see if they can double the supply of the company’s coronavirus vaccine by cutting doses in half. The study, though long planned, is increasingly urgent in the face of looming shortages as the country tries to fight off a surging pandemic.
Website crashes and tech glitches are afflicting the U.S. coronavirus vaccine rollout that is already behind schedule based on the goals the Trump administration set out.
Recent Comments